Jul 28, 2022

ST PHARM's Cutting-edge Technology to Reduce the Cost of Promising Drug

- RIGHT Fund, ST Pharm, and DNDi announced a partnership to find cost-effective ways to manufacture a promising drug for visceral leishmaniasis, one of the world’s most neglected diseases.

- ST Pharm will evaluate alternative processes to manufacture the API and optimize its production by reducing the number of processing steps. The company will also explore the use of its innovative continuous flow technology to improve the yield and purity of the API – as well as minimize waste in production, making the manufacturing process more environmentally friendly.

- This project will be conducted over a one-year period. If successful, DNDi and ST Pharm plan to conduct further process development and pilot the production of API for Phase III clinical trials.

[DNDi Press release]